JPH064669B2 - Polyene substance and obesity function regulator - Google Patents
Polyene substance and obesity function regulatorInfo
- Publication number
- JPH064669B2 JPH064669B2 JP1055862A JP5586289A JPH064669B2 JP H064669 B2 JPH064669 B2 JP H064669B2 JP 1055862 A JP1055862 A JP 1055862A JP 5586289 A JP5586289 A JP 5586289A JP H064669 B2 JPH064669 B2 JP H064669B2
- Authority
- JP
- Japan
- Prior art keywords
- substance
- cells
- polyene
- mast cell
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 title claims description 53
- 150000004291 polyenes Chemical class 0.000 title claims description 11
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 210000003630 histaminocyte Anatomy 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 6
- 230000003915 cell function Effects 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 229920002055 compound 48/80 Polymers 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000003463 adsorbent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- ALSPKRWQCLSJLV-UHFFFAOYSA-N azanium;acetic acid;acetate Chemical compound [NH4+].CC(O)=O.CC([O-])=O ALSPKRWQCLSJLV-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- GPZPVAIBXPRLFD-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O GPZPVAIBXPRLFD-UHFFFAOYSA-N 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187220 Streptomyces albireticuli Species 0.000 description 1
- 241000933209 Streptomyces eurocidicus Species 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- DTSSDPFTHGBSDX-KVTDHHQDSA-N mycosamine Chemical compound C[C@@H](O)[C@@H](O)[C@H](N)[C@H](O)C=O DTSSDPFTHGBSDX-KVTDHHQDSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical group CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000007487 urography Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Description
【発明の詳細な説明】 〔技術分野〕 本発明は、ポリエン物質及び肥満細胞機能調節剤に関す
るものである。TECHNICAL FIELD The present invention relates to a polyene substance and a mast cell function regulator.
肥満細胞は動物の結合組織及び消化管粘膜内に存在し、
細胞内にケミカルメディエーターと呼ばれる生物活性物
質を含む顆粒を数多く持っている。炎症性反応及びアレ
ルギー反応はともに、刺激を受けた肥満細胞が脱顆粒反
応を起こし、ヒスタミン、セロトニンなどのケミカルメ
ディエーターを放出するところから始まる。免疫グロブ
リンEの受容体を持つ細胞として肥満細胞が注目され、
肥満細胞における刺激の伝達機能及び脱顆粒反応の作用
機作などを解明することがアレルギー反応を理解するこ
とに直接つながるため、肥満細胞の脱顆粒作用及び脱顆
粒抑制作用等の機能調節作用をもつ物質の開発が望まれ
ている。Mast cells are present in the connective tissues of animals and in the gastrointestinal mucosa,
It has many granules containing biologically active substances called chemical mediators in its cells. Both an inflammatory reaction and an allergic reaction start when stimulated mast cells undergo a degranulation reaction and release chemical mediators such as histamine and serotonin. Mast cells are attracting attention as cells that have receptors for immunoglobulin E,
Since elucidation of the stimulus transmission function and the mechanism of action of degranulation reaction in mast cells directly leads to understanding of allergic reaction, it has function-regulating actions such as degranulation action and degranulation inhibition action of mast cells. Development of substances is desired.
そこで、本発明者らは、このような作用を有する物質の
開発について広く検討を行ったところ、下記一般式で示
される新規なポリエン物質が肥満細胞機能調節作用を有
することをはじめて明らかにし、本発明を完成させた。Therefore, the present inventors have extensively studied the development of a substance having such an action, and have revealed for the first time that a novel polyene substance represented by the following general formula has a mast cell function-regulating action, Completed the invention.
従って、本発明は新規なポリエン物質及び肥満細胞機能
調節剤を提供することを目的とする。Therefore, an object of the present invention is to provide a novel polyene substance and a mast cell function regulator.
本発明によれば、下記一般式で示されるポリエン物質及
び肥満細胞機能調節剤が提供される。According to the present invention, a polyene substance and a mast cell function regulator represented by the following general formula are provided.
前記式中、R1は水素原子又はアルキル基であり、アルキ
ル基としては、メチル、エチル、プロピル等の低級アル
キル基が挙げられる。R2は水素原子又は水酸基である。
R3は水素原子、塩形成性カチオン又はアルキル基であ
る。塩形成性カチオンとしては、ナトリウムやカリウム
等のアルカリ金属、カルシウムやマグネシウム等のアル
カリ土類金属の他、アルミニウム、アンモニウム、有機
アンモニウム等が挙げられる。アルキル基としては、メ
チル、エチル、プロピル等の低級アルキル基が挙げられ
る。 In the above formula, R 1 is a hydrogen atom or an alkyl group, and examples of the alkyl group include lower alkyl groups such as methyl, ethyl and propyl. R 2 is a hydrogen atom or a hydroxyl group.
R 3 is a hydrogen atom, a salt-forming cation or an alkyl group. Examples of the salt-forming cation include alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, as well as aluminum, ammonium and organic ammonium. Examples of the alkyl group include lower alkyl groups such as methyl, ethyl and propyl.
前記一般式(I)において、R3が水素原子であるポリエン
物質(以下、本物質とも言う)は、ストレプトベルティ
シリウム・ユーロシジカム (Streptoverticillium eurocidicum、IFO No.13491)株
又はストレプトベルティシリウム・アルビレティキュリ
(Streptoverticillium albireticuli、IFO No.12737)株
を、一般培地に培養し、培地中に産生させることができ
る。この場合の培養は、例えば、炭素源としてグルコー
ス、シュークロース、マルトース、デキトリン、澱粉、
グリセリン等を、窒素源としてはペプトン、肉エキス、
酵母エキス、麦芽エキス等を用い、さらに無機塩とし
て、NaCl、K2HPO4Na2HPO4、MgSO4等を加えた中性液体培
地中で、通気、攪拌することにより実施することができ
る。培地のpHは5〜8、好ましくは7付近で培養され
る。培養温度は通常、20〜35℃の範囲であるが、30℃付
近が好ましい。例えばグリコール1.5%、ペプトン0.5%、
肉エキス0.5%、酵母エキス0.5%、NaCl0.5%を含むpH7.0
の液体培地で28℃、40時間培養することにより、本物
質を生産させることができる。In the general formula (I), a polyene substance in which R 3 is a hydrogen atom (hereinafter, also referred to as this substance) is a Streptoverticillium eurocidicum (IFO No. 13491) strain or Streptoverticillium arubi Reticuli
The (Streptoverticillium albireticuli, IFO No. 12737) strain can be cultured in a general medium and produced in the medium. The culture in this case is performed by, for example, glucose, sucrose, maltose, dextrin, starch as a carbon source,
Glycerin, etc. as the nitrogen source, peptone, meat extract,
It can be carried out by using yeast extract, malt extract and the like, and aerating and stirring in a neutral liquid medium to which NaCl, K 2 HPO 4 Na 2 HPO 4 , MgSO 4 and the like have been added as inorganic salts. The medium is cultured at a pH of 5 to 8, preferably around 7. The culture temperature is usually in the range of 20 to 35 ° C, preferably around 30 ° C. For example, glycol 1.5%, peptone 0.5%,
PH 7.0 containing 0.5% meat extract, 0.5% yeast extract, 0.5% NaCl
This substance can be produced by culturing at 28 ° C. for 40 hours in the above liquid medium.
培養濾液からの本物質の採取は、有機溶媒抽出法、イオ
ン交換樹脂法、及び吸着剤を用いた吸脱着法や、高速液
体ウロマトグラフィー法等を用いて行うことができる。
例えば、培養濾液中に1/10体積量のアンバーライトXAD-
7を加えて時々攪拌しながら室温で約4時間吸着処理を
行った後、アンバーライトXAD-7を濾別し、これを洗浄
後、80%メタノール溶液で溶出処理する。溶出液を減圧
濃縮後、水に再溶解し、pH4.0に調整した後、CM−トヨ
パールイオン交換クロマトグラフィーを行うと、0.05M
酢酸−酢酸アンモニウムによるpHグラジエントによりpH
5.0付近から溶出が始まる。この溶出液をさらにpH9.0に
調整し、DEAE−トヨパールイオン交換クロマトグラフィ
ーを行うとpH7.5付近から溶出が始まる。さらに活性画
分を、MCIゲルCHP-20P吸着カラムに吸着させ、40%アセ
トニトリル溶出画分を分取した後、高速液体クロマトグ
ラフィー(HPLC)を用いることにより本物質を得ることが
できる。Collection of this substance from the culture filtrate can be carried out by an organic solvent extraction method, an ion exchange resin method, an adsorption / desorption method using an adsorbent, a high performance liquid urography method, or the like.
For example, 1/10 volume of Amberlite XAD- in the culture filtrate.
After adding 7 and adsorbing at room temperature for about 4 hours with occasional stirring, Amberlite XAD-7 is filtered off, washed, and then eluted with 80% methanol solution. The eluate was concentrated under reduced pressure, redissolved in water, adjusted to pH 4.0, and subjected to CM-Toyopearl ion exchange chromatography to give 0.05M.
PH with an acetic acid-ammonium acetate pH gradient
Elution starts from around 5.0. When this eluate is further adjusted to pH 9.0 and subjected to DEAE-Toyopearl ion exchange chromatography, elution begins around pH 7.5. Further, the active fraction is adsorbed on an MCI gel CHP-20P adsorption column, a 40% acetonitrile-eluted fraction is collected, and then this product can be obtained by using high performance liquid chromatography (HPLC).
さらに、本物質は菌体をメタノール等の有機溶媒を用い
る抽出処理した後、ODSカラム等による吸着クロマトグ
ラフィーを用い、溶出画分を濃縮、結晶化等の通常の精
製操作を行うことによっても得ることができる。Furthermore, this substance can also be obtained by subjecting the bacterial cells to an extraction treatment using an organic solvent such as methanol, and then using adsorption chromatography using an ODS column or the like to concentrate the elution fraction and carry out ordinary purification operations such as crystallization. be able to.
前記、一般式(I)においてR3が塩形成性カチオン及びア
ルキル基を示すものは、一般式(I)においてR3が水素原
子を示す物質に対し、それぞれ対応するカチオンを含む
塩基及びエステル化剤を常法により反応させることによ
って得ることができる。In the above general formula (I), R 3 represents a salt-forming cation and an alkyl group, a substance having a cation corresponding to R 3 in the general formula (I) is a base and esterification containing a corresponding cation. It can be obtained by reacting the agent by a conventional method.
また、本物質は、通常用いられる化学合成法もしくは酵
素を用いる合成法によっても得ることができる。ポリエ
ン物質あるいはそれに類するものとマイコースもしくは
マイコサミンなどを用いることにより本物質を合成する
ことができる。The substance can also be obtained by a commonly used chemical synthesis method or a synthetic method using an enzyme. This substance can be synthesized by using a polyene substance or the like and mycose or mycosamine.
次に、本発明を実施例によりさらに詳細に説明する。 Next, the present invention will be described in more detail with reference to examples.
実施例1 グルコース1.5%、ペプトン0.5%、肉エキス0.5%、酵素エ
キス0.5%、NaCl0.5%を含むpH7.5%の液体培地100mlを500
mlの坂口フラスコに分注し、120℃、20分間滅菌する。
この培地に放線菌ストレプトベルティシリウム・ユーロ
シジカム株の斜面寒天培地より1白金耳量を接種し、28
℃、3日間往復しんとう培養を行った。この培養液と同
組成の培地20を30用ジャーファーメンターに仕込
み、ストレプトベルティシリウム・ユーロシジカム株の
前培養液300mlをこの培地に移し、28℃、200回転、通気
量毎分10で40時間培養を行った。培養終了後、7000
回転の連続遠心を行うことにより、菌体と培養濾液とを
分離し、黒かっ色の培養濾液18を得た。この培養濾液
の肥満細胞脱顆粒抑制活性は642,500ユニットであっ
た。Example 1 500 ml of 100 ml of pH 7.5% liquid medium containing glucose 1.5%, peptone 0.5%, meat extract 0.5%, enzyme extract 0.5%, and NaCl 0.5%
Dispense into a ml Sakaguchi flask and sterilize at 120 ° C for 20 minutes.
This medium was inoculated with 1 platinum loop amount from a slope agar medium of Streptoverticillium eurosidicum strain of Streptomyces sp.
Reciprocating agitation culture was performed at 3 ° C for 3 days. A medium 20 having the same composition as this culture solution was charged into a jar fermenter for 30 and 300 ml of a preculture solution of the Streptoverticillium eurosidicum strain was transferred to this medium, and at 28 ° C., 200 rpm, and an aeration rate of 10 minutes, 40 hours. Culture was performed. 7,000 after culture
The cells were separated from the culture filtrate by continuous rotation centrifugation to obtain a black-brown culture filtrate 18. The mast cell degranulation inhibitory activity of this culture filtrate was 642,500 units.
実施例2 実施例1で得た菌体に5倍量のメタノールを加えて攪拌
後、室温にて放置した。時々攪拌しながら24時間置いた
後、菌体を濾別後、メタノール抽出液を同容量の水と混
合して、ODS吸着カラム(日本ミリポア製、カラム体積7
78ml、メタノール/水=1/1にて平衡化)に吸着させ
た。溶出液(メタノール/水=2/1)を用いてI,II及
びIIIの画分を順次得、濃縮、再結晶操作により、各画
分に対応する本物質NO.1:5.0mg、NO.2:8.7mg及びN
O.3:100mgを得た。Example 2 To the cells obtained in Example 1 was added 5 times the amount of methanol, the mixture was stirred, and then allowed to stand at room temperature. After leaving for 24 hours with occasional stirring, the bacterial cells were filtered off, and the methanol extract was mixed with an equal volume of water to obtain an ODS adsorption column (Nihon Millipore, column volume 7
78 ml, equilibrated with methanol / water = 1/1). Fractions I, II and III were sequentially obtained using the eluate (methanol / water = 2/1), and concentrated and recrystallized to give the corresponding substance NO.1: 5.0 mg, NO. 2: 8.7 mg and N
O. 3: 100 mg was obtained.
実施例3 (1)実施例1で得られた培養濾液のうち5中に、その1
/10体積に相当する吸着剤アンバーライトXAD-7を加え、
時々振とうしながら4時間室温にて吸着処理した。吸引
濾過におり、吸着剤を濾別し、精製水で洗浄した後、吸
着剤体積の2倍量に相当する20%メタノール水溶液で洗
浄した。その後、吸着剤体積の3倍量に相当する80%メ
タノール水溶液で溶出させ、溶出液を減圧濃縮した後、
精製水に溶解させた。ほぼ100%近い活性が回収できた。Example 3 (1) 1 out of 5 of the culture filtrates obtained in Example 1
/ 10 volume of adsorbent Amberlite XAD-7 is added,
Adsorption treatment was performed at room temperature for 4 hours with occasional shaking. In suction filtration, the adsorbent was filtered off, washed with purified water, and then washed with a 20% aqueous methanol solution corresponding to twice the adsorbent volume. Then, elute with 80% aqueous methanol solution corresponding to 3 times the adsorbent volume, and concentrate the eluate under reduced pressure.
It was dissolved in purified water. Almost 100% of the activity could be recovered.
(2)次に、CM−トヨパール650Mカラム〔東ソー製、カラ
ム体積533ml、0.05M酢酸−酢酸アンモニウム(pH4.0)で
平衡化〕にpH4.0に調整した試料溶液を吸着させ、0.05M
酢酸−酢酸アンモニウム(pH6.0)で溶出させた。活性画
分は溶出後のpH5.0から溶出してきた。活性画分の肥満
細胞脱顆粒抑制活性は25,250ユニットであった。(2) Next, a CM-Toyopearl 650M column (manufactured by Tosoh, column volume 533 ml, equilibrated with 0.05 M acetic acid-ammonium acetate (pH 4.0)) was adsorbed with a sample solution adjusted to pH 4.0, and 0.05 M was added.
It was eluted with acetic acid-ammonium acetate (pH 6.0). The active fraction began to elute at pH 5.0 after elution. The mast cell degranulation inhibitory activity of the active fraction was 25,250 units.
(3)さらに上記(2)の活性画分を、pH9.0に調整した後、D
EAE−トヨパール650Mカラム〔東ソー製、カラム体積179
ml、0.05M酢酸アンモニウム−アンモニア水でpH9.0に平
衡化〕に、吸着させ、0.05M酢酸アンモニウム−アンモ
ニア水(pH7.5)で溶出させた。この活性画分の活性は、1
6,500ユニットであった。(3) After further adjusting the active fraction of (2) above to pH 9.0,
EAE-Toyopearl 650M column [Tosoh, column volume 179
ml, equilibrated to pH 9.0 with 0.05 M ammonium acetate-ammonia water], and eluted with 0.05 M ammonium acetate-ammonia water (pH 7.5). The activity of this active fraction is 1
It was 6,500 units.
(4)さらに、MCIゲル(CHP-20P、三菱化成製)を充填した
吸着カラム(カラム体積40ml)に、前記(3)で得られた
活性画分を吸着させ、20%アセト−トリル水溶液で洗浄
後、40%アセトニトリル水溶液で溶出させ、減圧濃縮し
て白色物質を得た。(4) Furthermore, the active fraction obtained in (3) above was adsorbed to an adsorption column (column volume 40 ml) packed with MCI gel (CHP-20P, manufactured by Mitsubishi Kasei), and 20% aceto-tolyl aqueous solution was used. After washing, it was eluted with 40% aqueous acetonitrile solution and concentrated under reduced pressure to obtain a white substance.
得られた物質をメタノールに溶解させ、HPLCにて分離し
た。この場合の分離条件は次の通りである。The obtained substance was dissolved in methanol and separated by HPLC. The separation conditions in this case are as follows.
カラム :ヌクレオシル5C8充填、直径10mm 長さ250mm 使用溶媒:アセトニトリル/酢酸アンモニウム 緩衝液(0.01M、pH5.0)=35/65 流 速:4ml/分 検 出:紫外波長350nmにおける吸光度測定 試料濃度:0.2mg/ml 注入量 :200μl/回 上記条件にて物質NO.1、、NO.2及びNO.3に該当する画分
を分取し、減圧濃縮して物質NO.1:1.1mg、NO.2:1.5mg
及びNo.3:10mgを得た。Column: Nucleosyl 5C8 packed, diameter 10 mm, length 250 mm Solvent used: acetonitrile / ammonium acetate buffer (0.01 M, pH 5.0) = 35/65 Flow rate: 4 ml / min Detection: Absorbance measurement at UV wavelength 350 nm Sample concentration: 0.2 mg / ml Injection volume: 200 μl / times Under the above conditions, the fractions corresponding to substance NO.1, NO.2 and NO.3 were collected and concentrated under reduced pressure to obtain substance NO.1: 1.1 mg, NO .2: 1.5 mg
And No. 3: 10 mg were obtained.
実施例4 (1)物質NO.1、、NO.2及びNO.3をそれぞれ約1.5mgを正確
に計りとり、微量元素分析を行った。炭素、水素及び窒
素の含有率は、物質NO.1:C=57.59%、H=7.61%、N=1.
76%と、物質NO.2:C=57.70%、H=7.57%、N=1.65%、
物質NO.3:C=58.86%、H8.10%、N=1.86%と測定され、
それぞれ、C39H63O17N(理論値C=57.27%、H=7.76%、
N=1.71%)C40H65O17N(理論値:C=57.75%、H=7.87
%、N=1.68%)、C40H65O16N(C=58.88%、H=8.03%、N
=1.72%)の組成をもつものであると明らかになった。Example 4 (1) About 1.5 mg of each of the substances NO.1, NO.2 and NO.3 was accurately measured and trace element analysis was performed. The contents of carbon, hydrogen and nitrogen are as follows: NO.1: C = 57.59%, H = 7.61%, N = 1.
76% and substance NO.2: C = 57.70%, H = 7.57%, N = 1.65%,
Material NO.3: C = 58.86%, H8.10%, N = 1.86%,
C 39 H 63 O 17 N (theoretical value C = 57.27%, H = 7.76%,
N = 1.71%) C 40 H 65 O 17 N (Theoretical value: C = 57.75%, H = 7.87
%, N = 1.68%), C 40 H 65 O 16 N (C = 58.88%, H = 8.03%, N
= 1.72%).
(2)物質NO.1、、NO.2及びNO.3について、その質量分析を
行った。FAB-MS法による測定結果は、物質NO.1は、(M+
H)+=782.36となり、C39H59O15N(M=781.39)と判明し
た。物質NO.2は、(M+H)+=796.47となり、C40H61O15N(M
=795.40)と判明した。物質NO.3は、(M+H)+=780.45と
なり、C40H61O14N(M=799.41)と判明した。元素分析法
の値はそれぞれ2水塩(2H2O)であると推定された。(2) Mass spectrometry was performed on the substances NO.1, NO.2 and NO.3. FAB-MS measurement results show that substance No. 1 is (M +
H) + = 782.36, which proved to be C 39 H 59 O 15 N (M = 781.39). Material NO.2 becomes (M + H) + = 796.47, and C 40 H 61 O 15 N (M
= 795.40). The substance NO.3 became (M + H) + = 780.45, which was found to be C 40 H 61 O 14 N (M = 799.41). The elemental analysis values were estimated to be dihydrate (2H 2 O), respectively.
(3)物質NO.1、、NO.2及びNO.3をメタノールに溶解し紫外
線吸収スペクトル分析を行った。その結果は、物質NO.
1、NO.2及びNO.3はいずれも302nm、316nm、331nm及び34
9nmに極大波長を示すペンタエン構造であることが明ら
かとなり、吸収の強さはE(1%、MeOH)で表わすと、物質N
O.1では、398(302nm)、844(316nm)、1375(331nm)及び13
88(349nm)となり、物質NO.2では、344(302nm)、700(316
nm)、1122(331nm)及び1144(349nm)となり、物質NO.3で
は、362(302nm)、760(316nm)、1210(331nm)及び1232(34
9nm)となった。(3) The substances NO.1, NO.2 and NO.3 were dissolved in methanol and subjected to ultraviolet absorption spectrum analysis. The result is substance NO.
1, NO.2 and NO.3 are all 302 nm, 316 nm, 331 nm and 34
It was clarified that it has a pentaene structure with a maximum wavelength at 9 nm, and the absorption intensity is E (1%, MeOH).
In O.1, 398 (302 nm), 844 (316 nm), 1375 (331 nm) and 13
88 (349 nm), and for substance No. 2, 344 (302 nm), 700 (316 nm)
nm), 1122 (331 nm) and 1144 (349 nm) .For substance NO.3, 362 (302 nm), 760 (316 nm), 1210 (331 nm) and 1232 (34 nm).
9 nm).
(4)物質NO.1、、NO.2及びNO.3をそれぞれ約10μg計りと
り、臭化カリウムと混合して錠剤をつくり、KBrタブレ
ット法による赤外線吸収スペクトル分析法を行った。そ
の結果、各物質とも、3380cm-1、1700cm-1、1560cm-1、
1390cm-1、1070cm-1及び1005cm-1に吸収を示し、ポリエ
ン物質としての特徴を示していた。(4) About 10 μg of each of the substances NO.1, NO.2 and NO.3 was weighed and mixed with potassium bromide to prepare tablets, and infrared absorption spectrum analysis by the KBr tablet method was performed. As a result, for each substance, 3380 cm -1 , 1700 cm -1 , 1560 cm -1 ,
1390 cm -1, an absorption in 1070 cm -1 and 1005cm -1, showed the characteristics of a polyene material.
(5)物質NO.1、、NO.2及びNO.3をそれぞれ重水素置換ジメ
チルホルムアミド(DMF-d)もしくは重水素置換ジメチル
スルホキシド(DMSO-d)に溶解して核磁気共鳴スペクトル
を行った。1H核磁気共鳴スペクトル、13C核磁気共鳴ス
ペクトル、13C-DEPT測定及び1H-1Hシフト相関二次元核
磁気共鳴スペクトル分析を行い、各物質の構造は前記一
般式(I)において、物質NO.1の場合、R1=H、R2=OH、R3
=H、物質NO.2の場合、R1=CH3、R2=OH、R3=H、物質N
O.3の場合、R1=CH3、R2=H、R3=Hを示すものであるこ
とを決定した。(5) Substances NO.1, NO.2 and NO.3 were dissolved in deuterium-substituted dimethylformamide (DMF-d) or deuterium-substituted dimethylsulfoxide (DMSO-d), respectively, and nuclear magnetic resonance spectra were performed. . 1 H nuclear magnetic resonance spectrum, 13 C nuclear magnetic resonance spectrum, 13 C-DEPT measurement and 1 H- 1 H shift correlation two-dimensional nuclear magnetic resonance spectrum analysis, the structure of each substance in the general formula (I), In the case of substance NO.1, R 1 = H, R 2 = OH, R 3
= H, substance NO.2, R 1 = CH 3 , R 2 = OH, R 3 = H, substance N
In the case of O.3, it was determined that R 1 = CH 3 , R 2 = H, and R 3 = H.
実施例5 (1)ウィスター系雌性ラット(体重150〜250g)を脱血致
死させ、腹腔内にタイロード液を20ml注入し、腹部を約
2分間軽くマッサージした。開腹後覆水を採取し、4℃
にて150×g、10分間の条件で遠心分離し、沈澱する細
胞を集めた。この細胞をタイロード液2mlに懸濁させ、
比重1.068に調整した牛血清アルブミン含有生理食塩水4
mlに重層し、4℃、100×gの条件で12分間遠心分離
後、沈澱する細胞を集めた。タイロード液で2回洗浄し
た後、0.2%牛血清アルブミンを含むタイロード液に液に
肥満細胞が約106個/mlとなるように懸濁させ、肥満細
胞浮遊液を得た。Example 5 (1) Female Wistar rats (body weight 150 to 250 g) were killed by exsanguination, 20 ml of Tyrode's solution was intraperitoneally injected, and the abdomen was gently massaged for about 2 minutes. After laparotomy, cover water and collect at 4 ℃
Were centrifuged at 150 xg for 10 minutes to collect the precipitated cells. Suspend these cells in 2 ml of Tyrode's solution,
Saline containing bovine serum albumin adjusted to a specific gravity of 1.068 4
The cells were layered on top of each other, and centrifuged at 4 ° C. and 100 × g for 12 minutes, and then the precipitated cells were collected. After washing twice with Tyrode's solution, the solution was suspended in Tyrode's solution containing 0.2% bovine serum albumin so that mast cells were about 10 6 cells / ml to obtain a mast cell suspension.
(2)被験化合物を含む生理食塩水20μlと肥満細胞浮遊
液20μlを10分間37℃にて反応させ、最終濃度1μg/
mlとなるようにコンパウンド48/80溶液10μlを加え、
さらに10分間反応させた。反応後1分間氷冷した後、1,
500×g、4分間の条件で遠心し、上澄と細胞とを分離し
た。上澄に含まれるヒスタミンをOndaらのHPLC法(Hiro
chima J.Med.Sci,第27巻、93〜97ページ、1987年によ
り)定量することにより脱顆粒を測定した。この場合、
肥満細胞脱顆粒抑制活性は以下の式より算出した。(2) 20 μl of physiological saline containing the test compound and 20 μl of mast cell suspension were reacted at 37 ° C. for 10 minutes to give a final concentration of 1 μg /
Add 10 μl of compound 48/80 solution to make up to ml,
The reaction was continued for another 10 minutes. After the reaction was cooled in ice for 1 minute, 1,
The supernatant was separated from the cells by centrifugation at 500 xg for 4 minutes. Histamine contained in the supernatant was analyzed by the Onda et al. HPLC method (Hiro
Chima J. Med. Sci, 27, 93-97, 1987) was used to measure degranulation. in this case,
The mast cell degranulation inhibitory activity was calculated by the following formula.
A;細胞をコンパウンド48/80とのみ反応させ た時に遊離されたヒスタミン量 B;被験化合物を細胞と反応させた後、コンパウンド48
/80を加えてさらに反応させた時 に遊離されたヒスタミン量 C;細胞を緩衝液(もしくは生理食塩水)とのみ 反応させた時に遊離されたヒスタンミン量 脱顆粒誘発剤としては、コンパウンド48/80(シグマ社
製)の他、コンカナバリンA、イオノフォアA23187はじ
め一般に知られている任意の薬剤を用いることができ
る。 A: Amount of histamine released when cells were reacted only with compound 48/80 B; Compound 48 was reacted with the test compound and then reacted with compound 48/80
/ 80 added histamine amount when further reacted C; Histamine amount released when cells were reacted only with buffer (or physiological saline) Compound 48/80 as a degranulation inducer In addition to (manufactured by Sigma), concanavalin A, ionophore A23187 and any other generally known drug can be used.
被験化合物の濃度を種々変えて測定を行い、本測定系で
1μg/mlのコンパウンド48/80により誘発される肥満細
胞脱顆粒を50%抑制する化合物の濃度〔IC50〕値を
求めた。また、コンパウンド48/80の存在しない状態
や、コレステロールを添加した状態など各種の状態や、
コレステロールを添加した状態など各種の条件下で本物
質を肥満細胞に対する機能調節作用の測定も合せて行
い、その結果は以下に示すように、本物質には、強い肥
満細胞機能調節作用をもつことが認められた。The concentration of the test compound was changed variously, and the concentration [IC 50 ] value of the compound that inhibits 50% of mast cell degranulation induced by 1 μg / ml of compound 48/80 in this measurement system was determined. Also, various conditions such as the absence of compound 48/80, the condition of adding cholesterol,
Measurement of the function-regulating action of this substance on mast cells under various conditions such as the addition of cholesterol was also performed, and the results show that this substance has a strong mast-cell function regulating action. Was recognized.
なお、本測定系で1μg/mlコンパウンド48/80により
誘発される肥満細胞脱顆粒作用を50%抑制する化合物の
濃度を1単位/ml〔1ユニット/ml〕とした。The concentration of the compound that suppresses 50% of the mast cell degranulation action induced by 1 μg / ml compound 48/80 in this assay system was 1 unit / ml [1 unit / ml].
(3)1mg/mlのコンパウンド48/80の誘発する肥満細胞脱
顆粒作用に対して物質NO.1、NO.2及びNO.3の示した作用
は次の通りであった。(3) The effects of substances NO. 1, NO. 2 and NO. 3 on the mast cell degranulation effect induced by 1 mg / ml of compound 48/80 were as follows.
(3)−(i) 物質NO.1、NO.2及びNO.3は低濃度領域では肥満細胞脱顆
粒抑制作用を示し、そのIC50値は、物質NO.1:3.6μg
/ml、物質NO.2:1.8μg/ml、物質NO.3:1.0μg/ml
であった。(3)-(i) Substances NO.1, NO.2 and NO.3 show mast cell degranulation inhibitory action in the low concentration region, and its IC 50 value is substance NO.1: 3.6 μg
/ Ml, substance NO.2: 1.8 μg / ml, substance NO.3: 1.0 μg / ml
Met.
(3)−(ii) 物質NO.1、NO.2及びNO.3は高濃度領域では単独で肥満細
胞脱顆粒作用を示し、本作用は、反応液のカルシウムイ
オン濃度を約1mM以上にした時に発現し、反応液のカル
シウムイオン濃度が0に近い時は発現しないというカル
シウムイオン依存性を示した。(3)-(ii) Substances NO.1, NO.2 and NO.3 showed mast cell degranulation action alone in the high concentration region, and this action increased the calcium ion concentration of the reaction solution to about 1 mM or more. There was a calcium ion dependency that it was sometimes expressed and was not expressed when the calcium ion concentration of the reaction solution was close to zero.
(3)−(iii) 反応液にコレステロールを一定濃度(約2μg/ml)以上
加えることにより、上記(3)−(i)及び(3)−(ii)の作用
はコレステロールに対して濃度依存的に減少した。(3)-(iii) The action of (3)-(i) and (3)-(ii) above depends on the concentration of cholesterol by adding cholesterol to the reaction solution at a certain concentration (about 2 μg / ml) or more. Decreased.
実施例6 物質NO.1を100mg計りとり、ジメチルスルホキシド2mlに
溶解した後、無水メタノール0.2mlを加えて希釈した。
0.3モル濃度のジアゾメタンを含むテトラヒドロフラン1
mlをこれに加えて4℃にて約2分間反応させ、エステル
化を行った。反応液に無水エチルエーテル20mlを加えて
沈殿する物質を遠心にて集め、少量の無水エチルエーテ
ルにて洗浄後、同溶媒にて再結晶化操作を行い、物質N
O.1のメチルエステル(前記一般式(I)においてR1=C
H3、R2=H、R3=CH3を示すもの)、72mgを得た。Example 6 100 mg of the substance NO.1 was weighed and dissolved in 2 ml of dimethyl sulfoxide, and then 0.2 ml of anhydrous methanol was added to dilute it.
Tetrahydrofuran containing 0.3 molar diazomethane 1
Esterification was performed by adding ml to this and reacting at 4 ° C. for about 2 minutes. 20 ml of anhydrous ethyl ether was added to the reaction mixture, and the precipitated substance was collected by centrifugation, washed with a small amount of anhydrous ethyl ether, and recrystallized in the same solvent to give substance N.
The methyl ester of O.1 (in the general formula (I), R 1 ═C
H 3 , R 2 = H, R 3 = CH 3 ), 72 mg were obtained.
メチルエステルの同定は質量分析及び核磁気共鳴スペク
トル分析により行った。The methyl ester was identified by mass spectrometry and nuclear magnetic resonance spectroscopy.
以上のように、本発明により、特定のポリエン物質が肥
満細胞機能調節作用を有することが明らかにされた。As described above, according to the present invention, it was revealed that a specific polyene substance has a mast cell function regulating action.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 C12R 1:01) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location C12R 1:01)
Claims (2)
は水酸基、R3は水素原子、塩形成性カチオン又はアルキ
ル基を示す)1. A polyene substance represented by the following general formula. (In the formula, R 1 represents a hydrogen atom or an alkyl group, R 2 represents a hydrogen atom or a hydroxyl group, R 3 represents a hydrogen atom, a salt-forming cation or an alkyl group)
機能調節剤2. A mast cell function regulator comprising the polyene substance according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1055862A JPH064669B2 (en) | 1988-03-09 | 1989-03-08 | Polyene substance and obesity function regulator |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5558088 | 1988-03-09 | ||
JP63-55580 | 1988-03-09 | ||
JP1055862A JPH064669B2 (en) | 1988-03-09 | 1989-03-08 | Polyene substance and obesity function regulator |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH021498A JPH021498A (en) | 1990-01-05 |
JPH064669B2 true JPH064669B2 (en) | 1994-01-19 |
Family
ID=26396468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1055862A Expired - Lifetime JPH064669B2 (en) | 1988-03-09 | 1989-03-08 | Polyene substance and obesity function regulator |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH064669B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU655327B2 (en) * | 1991-10-21 | 1994-12-15 | Symbiosis Corporation | Double acting, dual pivot disposable endoscopic surgical instruments |
US6302616B1 (en) | 1999-09-01 | 2001-10-16 | Olympus Optical Co., Ltd. | Rotation mechanism including rotation shaft and fixed member with welding structure, and producing method of the same |
-
1989
- 1989-03-08 JP JP1055862A patent/JPH064669B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH021498A (en) | 1990-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0273388A2 (en) | Sialic acid derivatives having active carbonyl group | |
NZ227113A (en) | Synthesis of amikacin | |
EP3712162B1 (en) | Smac mimetics used as iap inhibitors and use thereof | |
JPH03130299A (en) | Peptide compound and its preparation, and use thereof | |
JPH05247078A (en) | Sugar compound, sialic acid-containing sugar chain biosyhnthesis inhibitor, its production, and new intermediate | |
JPH064669B2 (en) | Polyene substance and obesity function regulator | |
Syed et al. | 9-BBN as a convenient protecting group in functionalisation of hydroxylysine | |
EP0315973A2 (en) | Sialocylglycerolipids and method for preparing the same | |
CN1097761A (en) | Polycyclic compound and its preparation method | |
JP3024864B2 (en) | Ellagic acid glycoside and method for producing the same | |
Igarashi et al. | Resormycin, a Novel Herbicidal and Antifungal Antibiotic Produced by a Strain of Streptomyces platensis II. Structure Elucidation of Resormycin | |
JP3110474B2 (en) | Oligosialyl-1,2-dialkyl-Sn-glycerol and synthetic intermediates thereof | |
JPH11269178A (en) | Production of pyridinium compound, and compound therefor | |
US5152999A (en) | Liposome preparation | |
CA1285936C (en) | 3-acylamino-3-deoxyallose derivatives | |
RU2304583C1 (en) | Method for synthesis di- and triaminochlorines | |
JPH06157394A (en) | Method for synthesizing Benastatin C and D | |
JP3134010B2 (en) | Desalanine benanomycin A derivatives and methods for their production | |
JPH0415770B2 (en) | ||
JP2578044B2 (en) | Phenylalanine-glycine derivative, method for producing the same, and antitumor agent containing the derivative | |
JPH0559046A (en) | Immunomodulator | |
JPH0635467B2 (en) | Novel glycosylation method | |
JP4334194B2 (en) | Echinasaidin 786 and method for obtaining the same | |
JP3026041B2 (en) | hCG-related 9-saccharide hapten | |
JPH0429356B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |